The Jane Calmes ALS Scholarship Fund wants to help support students who wish to pursue undergraduate studies, but whose families have been impacted financially by amyotrophic lateral sclerosis (ALS). This is the fourth year The ALS Association, together with Mark Calmes, is offering support to U.S. post-high…

Blocking channels containing the connexin 43 (Cx43) protein on astrocytes — a type of nerve support cell — slowed disease progression in a mouse model of amyotrophic lateral sclerosis (ALS), a study found. The protein was found to be increased in ALS patient tissues and spinal fluid, and its…

My husband, Todd, gets twice-weekly physical therapy, which significantly improves his quality of life with ALS. Six years ago, Todd was having pain in his shoulders, and his elbows would not fully straighten, making it difficult for him to use his wheelchair. His doctor ordered physical and occupational therapy evaluations…

A first healthy volunteer has been enrolled in a Phase 1 trial and given a first dose of PrimeC, an investigational combination therapy for people with amyotrophic lateral sclerosis (ALS), the treatment’s developer, NeuroSense Therapeutics, announced. The open-label Phase 1 trial (NCT05232461) is a pharmacokinetic study,…

Team Drea Foundation is launching a customizable wellness challenge that seeks to raise $50,000 in 50 days for amyotrophic lateral sclerosis (ALS) research. The 50for50 challenge invites people to set a personal goal related to the number 50, such as 50 pushups a day or 50 acts…

I’d like to send a hearty congratulations to us all! Why the celebration? Well, we’ve survived the first three months of the year in a world that continues to surprise and challenge us. Plus, for many who live with amyotrophic lateral sclerosis (ALS), making it through another three months justifies…

Regulus Therapeutics, in partnership with researchers at Brigham and Women’s Hospital, has initiated studies to evaluate a library of molecules designed to suppress microRNA-155 (miR-155) — a small molecule that regulates the activity of other genes — as a potential treatment for amyotrophic lateral sclerosis (ALS). The agreement, effective…

A new rapid test is under development that will be able to detect seafood and water levels of an environmental toxin called beta-N-methylamino-L-alanine (BMAA), the exposure to which has been implicated as a risk factor for amyotrophic lateral sclerosis (ALS). The efforts will be spearheaded by Brain Chemistry…

A novel system that involves electrodes implanted in the brain allowed a 34-year-old man with amyotrophic lateral sclerosis (ALS) who had completely lost the ability to move voluntarily — known as a “locked-in” state — to communicate with his family again. Using the system, the man was able to…

Two independent teams of scientists have unraveled the molecular mechanism by which abnormal localization of the TDP-43 protein, which is characteristic of amyotrophic lateral sclerosis (ALS), leads to reduced levels of another protein, called UNC13A, that is important for nerve cell function. The results also show that certain variations…